Related Experiment Video
Updated: Jan 13, 2026

07:49
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
3.1K
Mitochondrial Dynamics in Blood Cancer Development and Progression
Saurav Doshi1,2,3,4, Christina Glytsou1,2,3,4,5
1Graduate Program in Pharmaceutical Sciences, School of Graduate Studies, Rutgers University, Piscataway, 08854 NJ USA.
Current Pharmacology Reports
|October 28, 2025
Summary
Blood cancer cells manipulate mitochondrial dynamics for growth and drug resistance. Targeting these processes offers new therapeutic strategies and predictive biomarkers for hematologic malignancies.
Area of Science:
- Cell Biology
- Cancer Biology
- Mitochondrial Biology
Background:
- Mitochondrial dynamics, involving fusion and fission, are crucial for cellular homeostasis.
- Dysregulation of mitochondrial dynamics is linked to various chronic diseases.
- Cancer cells, particularly blood cancers, exploit mitochondrial remodeling for survival and progression.
Purpose of the Study:
- To review the role of mitochondrial dynamics in healthy cells.
- To elaborate on how blood cancer cells hijack mitochondrial processes.
- To explore therapeutic avenues targeting mitochondrial dynamics in hematologic malignancies.
Main Methods:
- Review of recent research on mitochondrial dynamics in cancer.
- Analysis of studies using cell lines, patient-derived samples, and xenograft models.
- Investigation of regulatory mechanisms of mitochondrial dynamics proteins.
Main Results:
- Blood cancer cells utilize mitochondrial plasticity for uncontrolled proliferation, stemness, and drug resistance.
- Leukemia and lymphoma cells adapt to stress and evade therapy by manipulating mitochondria.
- Mitochondrial dynamics proteins play specific roles in different hematologic malignancies and therapy resistance.
Conclusions:
- Modulating mitochondrial dynamics presents a promising therapeutic strategy for hematologic malignancies.
- Targeting mitochondrial dynamics regulators may serve as predictive biomarkers.
- Further integrated studies are needed to fully exploit mitochondrial vulnerabilities in blood cancers.
Related Concept Videos
Mitochondrial Membranes
16.6K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
16.6K
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K

